RenovoRx, Inc.: BOSTON SCIENTIFIC CORP amends Schedule 13G stake filing
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 6 November 2026, by SEC EDGAR SCHEDULE 13G
25
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Boston Scientific Corp. filed an amended Schedule 13G with the SEC (accession 0001104659-26-123910) updating its beneficial ownership stake in RenovoRx, Inc. The amendment discloses a change to Boston Scientific's previously reported position in the clinical-stage oncology company. The filing matters because it signals a shift in the strategic investor's holdings in RenovoRx. Investors will watch for further 13G amendments or 13D filings that could indicate a more active role.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
RenovoRx, Inc., Boston Scientific Corp